Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are investigating new treatment options for people living with HIV-1, focusing on improving the current standard of care. The study compares a new once-weekly antiretroviral therapy ART combining islatravir and ulonivirine to the standard daily ART regimen, which includes multiple medications taken up to twice a day. This research aims to evaluate if the new study ART works as well as the current standard treatment, while also assessing its safety and how well participants tolerate it. Participants will be randomly assigned to one of several groups one group will receive the study drugs islatravir and ulonivirine once weekly, another will take the standard ART daily, and two additional groups will receive combinations of study drugs and placebos for 96 weeks. The study involves both phase 2 and phase 3 parts, with participants taking their assigned medication orally either once daily or once weekly during this period. Throughout the study, participants will attend regular visits for up to 96 weeks where researchers will monitor their HIV-1 RNA levels, CD4 T-cell counts, body weight, and any adverse events. The main measurement is the percentage of participants with HIV-1 RNA below 50 copiesmL at weeks 24 and 48 for phase 2 and phase 3 respectively. Safety and tolerability will also be closely observed, including any discontinuation due to adverse events. Participants health will be followed through various laboratory tests and assessments during the study period.
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.
Actively Recruiting
Researchers are studying the use of zilovertamab vedotin ZV combined with standard treatments for participants aged 18 and older who have relapsed or refractory diffuse large B-cell lymphoma rrDLBCL. This Phase 23, randomized, open-label study aims to evaluate the safety and effectiveness of ZV with treatments like rituximab, gemcitabine, and oxaliplatin R-GemOx, or bendamustine and rituximab BR. The study has two parts Dose Confirmation and Efficacy Expansion, focusing on progression-free survival and other outcomes. Participants will receive intravenous infusions of ZV at doses ranging from 1.5 mgkg to 2.5 mgkg along with R-GemOx or BR depending on their assigned group. Treatments are given on Day 1 of repeated 21-day cycles, continuing for up to six cycles or until disease progression or discontinuation. Some participants will receive standard R-GemOx or BR treatments without ZV. Prophylactic granulocyte colony-stimulating factor G-CSF is also given at each cycle of ZV as per guidelines. During the study, participants undergo assessments including monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations over several months. Researchers will measure overall survival, progression-free survival, objective response rate, and duration of response. Participants will be closely followed for up to approximately 68 months to track safety and effectiveness outcomes throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of QMF149 a combination of indacaterol acetate and mometasone furoate compared to budesonide in children aged 6 to less than 12 years who have asthma. This Phase 3, double-blind, randomized, active-controlled crossover study aims to determine whether QMF149 is superior in improving lung function measured by FEV1 in these children, who have at least 50% of the predicted normal value of FEV1. Participants undergo two treatment periods, each lasting 12 weeks, receiving either QMF149 7540 mcg once daily via Breezhaler or budesonide 200 mcg once daily via Breezhaler in a crossover design. The study includes a screening period of up to 3 weeks, a 3-week run-in period with fluticasone propionate 50 mcg twice daily, a 3-week washout period with the same medication, and a 4-week safety follow-up during which participants return to standard care. The total study duration is up to 37 weeks. Throughout the study, participants will attend visits at defined intervals, including screening, run-in, treatment, washout, and follow-up periods. Researchers will assess lung function changes FEV1, asthma control questionnaire scores, peak expiratory flow rates, rescue medication use, and monitor adverse events. Safety information and survival status will be collected after the follow-up period to ensure thorough evaluation of both treatments.
Actively Recruiting
Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects of antibiotic treatment on asymptomatic bacteriuria AB during pregnancy in low- and middle-income countries. This phase 3 randomized controlled trial aims to reduce the incidence of small vulnerable newborns SVN and stillbirths SB, contributing to global health goals to prevent early childhood deaths. The study involves pregnant individuals and newborns across seven international sites collaborating with the NICHD Global Network for Womens and Childrens Health Research. Participants with AB are randomly assigned to one of two groups one group receives a 7-day course of oral nitrofurantoin monohydratemacrocrystals at 100 mg twice daily 14 doses total, while the other group receives a matching placebo on the same schedule. The study compares the impact of this antibiotic treatment versus placebo during pregnancy. During the study, participants will complete screening, randomization, treatment, and follow-up visits, with monitoring continuing until 42 days after birth. Researchers will assess the number of small vulnerable newborns or stillbirths as the main outcome. Participants must remain in the study area for the full postpartum follow-up period, during which health and safety are monitored carefully.
1-10 of 25
1